Form D · Biotechnology
Innervace, Inc.
New York, NY · CIK 0001941327
Offering snapshot reported Aug 22, 2022 · SEC filing
- Reported sold
- $10M Offering amount: $40M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 8, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 22, 2022 | Initial | $9,999,973 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456567
Source: Form D, filed Aug 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Greenwald | Director |
| Nader Halim | Director, Executive |
| Jonathan Leff | Director |
| Althea Stillman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
345 Park Avenue South
New York, NY, 10010
New York, NY, 10010